SCHEMBL3013160

SCHEMBL3013160

O=S(=O)(c1ccc(F)c(Cl)c1)C1CCN(c2nc(-c3ccc(Cl)cc3Cl)cs2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 0.55
NPSR1 Q6W5P4 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
EPHX2 P34913 1/20 0.38
LMNA P02545 2/20 0.38
MAPT P10636 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
RORC P51449 1/20 0.37
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
DRD2 P14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016907 0.92 AR (0.57) ARNPSR1SMN1; SMN2RAB9ANPC1
SCHEMBL3002708 0.91 AR (0.56) ARNPSR1SMN1; SMN2RAB9ANPC1
SCHEMBL3017157 0.91 AR (0.60) ARNPSR1SMN1; SMN2RAB9ANPC1
SCHEMBL3021277 0.89 AR (0.60) ARNPSR1SMN1; SMN2RAB9ANPC1
SCHEMBL3015599 0.89 AR (0.53) ARNPSR1SMN1; SMN2RAB9ANPC1
SCHEMBL3003356 0.88 AR (0.57) ARNPSR1SMN1; SMN2RAB9ANPC1
SCHEMBL3018834 0.87 AR (0.56) ARNPSR1SMN1; SMN2RAB9ANPC1
SCHEMBL3002625 0.87 AR (0.56) ARNPSR1SMN1; SMN2RAB9ANPC1
SCHEMBL3011801 0.87 SMN1; SMN2 (0.51) ARNPSR1SMN1; SMN2RAB9ANPC1
SCHEMBL3014639 0.87 SMN1; SMN2 (0.48) ARNPSR1SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885NPSR1 764/4885SMN1; SMN2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.